Author

J. G. Hurdle

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:C. elegans· 4 Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Approach:mechanistic / dynamical model· 1 Assay:metabolomics· 1

Frequent Co-Authors

A. Deshpande· 2 shared A. O. Olaitan· 2 shared C. Dureja· 2 shared K. E. Hevener· 2 shared K. L. Palmer· 2 shared R. K. R. marreddy· 2 shared A. J. Gonzales-Luna· 1 shared C. C. Stephan· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Deshpande

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy

C. Dureja, J. T. Rutherford, F. B. A. Pavel, K. Norseeda, I. Prah, D. Sun, K. E. Hevener, J. G. Hurdle

This study evaluates the in vivo efficacy of phenylimidazole 296 against C. difficile by targeting CdFabK, showing it retains microbiome stability better than vancomycin and fidaxomicin.

bioRxiv · Sep 22, 2023 · PreprintMicrobiology

Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile

A. O. Olaitan, C. Dureja, M. Youngblom, M. A. Topf, W.-J. Shen, A. J. Gonzales-Luna, A. Deshpande, K. E. Hevener, J. Freeman, M. H. Wilcox, K. L. Palmer, K. W. Garey, C. S. Pepperell, J. G. Hurdle

This study identifies a mutation in C. difficile that causes metronidazole resistance and links it to fluoroquinolone resistance, contributing to the spread of drug-resistant strains.

bioRxiv · Sep 23, 2022Microbiology

The licorice metabolite enoxolone attenuates Clostridioides difficile pathophysiology by corrupting its metabolic and toxin production networks

R. K. R. marreddy, J. A. Picker, G. Phelps, R. T. Powell, P. Cherian, J. Bowling, C. C. Stephan, R. Lee, J. G. Hurdle

This paper identifies enoxolone, a licorice metabolite, as an inhibitor of C. difficile toxin production by disrupting metabolic pathways, showing improved efficacy when combined with vancomycin in a mouse model.

bioRxiv · Apr 20, 2022 · PreprintMicrobiology

Ebselen Exhibits Antimicrobial Activity Against Clostridioides difficile By Disrupting Redox Associated Metabolism

R. K. R. Marreddy, A. O. Olaitan, J. May, M. Dong, J. G. Hurdle

This study shows ebselen inhibits C. difficile by disrupting redox metabolism and toxin production, with bactericidal effects beyond its previously known anti-toxin activity.

bioRxiv · Jul 27, 2020 · PreprintMicrobiology

Chromosomal Resistance to Metronidazole in Clostridioides difficile can be Mediated By Epistasis Between Iron Homeostasis and Oxidoreductases

A. Deshpande, X. Wu, W. Huo, K. L. Palmer, J. G. Hurdle

This study identifies multi-genetic mechanisms of metronidazole resistance in C. difficile, showing epistasis between iron homeostasis and oxidoreductases.

bioRxiv · Mar 4, 2020Microbiology